Details
Stereochemistry | ACHIRAL |
Molecular Formula | CO3.2Fe.4Mg.12HO |
Molecular Weight | 473.007 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Fe+3].[Fe+3].[O-]C([O-])=O
InChI
InChIKey=HBHWBHDZABTVTA-UHFFFAOYSA-A
InChI=1S/CH2O3.2Fe.4Mg.12H2O/c2-1(3)4;;;;;;;;;;;;;;;;;;/h(H2,2,3,4);;;;;;;12*1H2/q;2*+3;4*+2;;;;;;;;;;;;/p-14
Molecular Formula | Fe |
Molecular Weight | 55.845 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | HO |
Molecular Weight | 17.0073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Mg |
Molecular Weight | 24.305 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | CO3 |
Molecular Weight | 60.0089 |
Charge | -2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
FERMAGATE is a phosphate binder with phosphate plasma levels lowering activity. It is in Phase 3 development in the US and in Europe for the treatment of hyperphosphatemia in dialysis patients. It is made up of magnesium and ferric iron atoms held in an insoluble, rigid, crystalline-layered structure, with carbonate groups lying between the layers. Upon oral administration, the carbonate ions in FERMAGATE are exchanged for free phosphate ions released from food in the gastrointestinal tract; thereby, strongly binding phosphate. This inhibits phosphate uptake and preventing hyperphosphatemia.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25815172
Recommended daily dose: 3000 mg, three pills per day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:52:24 GMT 2023
by
admin
on
Sat Dec 16 01:52:24 GMT 2023
|
Record UNII |
4VNO5L64GQ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4VNO5L64GQ
Created by
admin on Sat Dec 16 01:52:24 GMT 2023 , Edited by admin on Sat Dec 16 01:52:24 GMT 2023
|
PRIMARY | |||
|
96492-32-9
Created by
admin on Sat Dec 16 01:52:24 GMT 2023 , Edited by admin on Sat Dec 16 01:52:24 GMT 2023
|
PRIMARY | |||
|
56649436
Created by
admin on Sat Dec 16 01:52:24 GMT 2023 , Edited by admin on Sat Dec 16 01:52:24 GMT 2023
|
PRIMARY | |||
|
DTXSID10242277
Created by
admin on Sat Dec 16 01:52:24 GMT 2023 , Edited by admin on Sat Dec 16 01:52:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS |